ClinicalTrialsFinder
RecruitingPhase 2NCT04511078

Phase II Panitumumab-IRDye800 in Head & Neck Cancer

Phase II Open-Label Study Evaluating Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Head and Neck Cancer During Surgical Procedures

Sponsor

University of Alabama at Birmingham

Enrollment

25 participants

Start Date

Apr 2, 2021

Study Type

INTERVENTIONAL

Conditions

Head and Neck Cancer

Summary

The purpose of this study is to determine if panitumumab-IRDye800 is effective in identifying cancer, compared to surrounding normal tissue, and the further characterize the safety profile of this drug.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study tests a fluorescent dye attached to an antibody (panitumumab-IRDye800) that can be given before surgery to make head and neck cancer cells glow under a special surgical camera, helping surgeons more precisely remove cancer while sparing healthy tissue. **You may be eligible if...** - You have been diagnosed with squamous cell carcinoma of the head and neck (any location) - You are scheduled for surgical removal of the tumor with the goal of cure - You are 18 or older - You are in adequate health to undergo surgery **You may NOT be eligible if...** - You are not scheduled for surgery - You have had a prior serious allergic reaction to panitumumab or similar antibodies - You have uncontrolled infections or serious medical conditions preventing surgery - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGPanitumumab-IRDye800

single dose infusion of panitumumab-IRDye800CW

Locations(1)

University of Alabama at Birmingham

Birmingham, Alabama, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04511078

Related Trials

DESTINY-PANTUMOUR04

NCT0712400017 locations

Nutritional Status of Head and Neck Cancer Patients

NCT070687111 location

Velopharyngeal Dysfunction in Head & Neck Cancer Patients, Pilot Study

NCT072640361 location

ATATcH Alternating Treatment Plans for Advanced Cancer

NCT0535854811 locations

Methotrexate, Erlotinib, and Celecoxib for the Treatment of Recurrent/Metastatic Head and Neck Cancer in a Rural Midwest United States Population

NCT069970681 location